

OPEN ACCESS

EDITED BY Hanyao Huang, Sichuan University, China

REVIEWED BY Vassilios Tsitouras, Aristotle's University, Greece Hiroki Kajita, Keio University, Japan

*CORRESPONDENCE
Huthaifa Atallah

☑ h.atallah@ju.edu.jo
RECEIVED 30 May 2025
ACCEPTED 21 July 2025

PUBLISHED 31 July 2025

CITATION

Atallah H, Naeem R, Albeetar R, Qufabz T, AlFatafta M, Alshawabka A, Said AS, McGarry A, Derkács E, Varga D and Molics B (2025) 3D-printed cranial helmet therapy for the treatment of deformational plagiocephaly. Front. Pediatr. 13:1638581. doi: 10.3389/fped.2025.1638581

COPYRIGHT

© 2025 Atallah, Naeem, Albeetar, Qufabz, AlFatafta, Alshawabka, Said, McGarry, Derkács, Varga and Molics. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

3D-printed cranial helmet therapy for the treatment of deformational plagiocephaly

Huthaifa Atallah^{1*}, Rabee Naeem², Raghad Albeetar², Titeana Qufabz¹, Mahmoud AlFatafta¹, Amneh Alshawabka¹, Anas S. Said³, Anthony McGarry⁴, Evelin Derkács⁵, Dorottya Varga⁵ and Bálint Molics⁶

¹Prosthetics and Orthotics Department, School of Rehabilitation Sciences, The University of Jordan, Amman, Jordan, ²Digital Fabrication Division, Revolutionary Technologies for Medical Solutions, Amman, Jordan, ³Neurosurgery Department, Al Basheer Hospital, Amman, Jordan, ⁴Biomedical Engineering Department, University of Strathclyde, Glasgow, United Kingdom, ⁵Doctoral School of Health Sciences, Faculty of Health Sciences, University of Pécs, Pécs, Hungary, ⁶Department of Sport Physiotherapy, Faculty of Health Sciences, University of Pécs, Pécs, Hungary

Introduction: Deformational Plagiocephaly (DP) is the most common cranial deformity in infants. It may be treated using molding cranial helmet therapy (CHT) or active counter-positioning (ACP). Molding CHT has proven to be highly effective, especially in moderate to severe cases. Although many studies have explored this topic, few have investigated the use of 3D-printed CHT. This method may offer greater accuracy and convenience in measurement compared to traditional helmet types. Furthermore, no studies on this subject have been conducted in the Middle East.

Study design: A retrospective study design.

Methods: Electronic medical records from the only medical center fitting infants with 3D-printed CHT were reviewed. Infants diagnosed with DP who were fitted with and completed treatment using 3D-printed CHT were included. Infants who received 3D-printed CHT for other cranial deformities were excluded. Descriptive statistics (mean ± SD) were used to present results related to Cranial Vault Asymmetry Index (CVAI) and participants' characteristics. A Linear Mixed Model was used to assess changes in CVAI over time, accounting for age, gender, and treatment duration. Model assumptions were tested, and findings were validated using a Wilcoxon signed-rank test.

Results: Records of eleven infants diagnosed with DP were included, eight boys and three girls. A significant reduction in CVAI was reported in all cases. No significant correlation was found between CVAI improvement and gender, age, or treatment duration.

Conclusion: Following treatment with customized 3D-printed CHT, infants in the study demonstrated significant improvement in the CVAI. The helmets effectively guided cranial growth toward the flattened area, aiding in the correction of the deformity. Although 3D-printed CHT showed results comparable to traditional molding CHT, it offers potential advantages such as increased measurement accuracy through 3D scanning, easier monitoring of progress, and reduced cost and time associated with fabrication through 3D printing.

KEYWORDS

3D-printed helmet, deformational plagiocephaly, CVAI, cranial deformity, cranial helmet therapy

Introduction

Deformational plagiocephaly (DP) is a multiplanar asymmetric and a non-synostotic skull deformity that can occur either before or after birth (1–3). It is considered the most common type of cranial asymmetry in infants (4). DP typically presents as flattening on one side of the occiput, but it can also affect both sides, as seen in brachycephaly. Reported cases have increased by up to 600% as reported in the literature after "Back to Sleep" (5). "Back to sleep" was a campaign launched in April 1992 by the American Academy of Pediatrics (AAP), was geared towards preventing sudden infant death syndrome (SIDS) (6). About 70% of normal infants in Japan, between 1 and 7 months-old, have DP (7).

The primary associated factors for developing DP are specific nursing habits, motor development, and positional preference (8). Other reported risk factors are premature birth, multiple births, restrictive intrauterine environment, delivery by forceps or vacuum extraction and male gender (3, 9, 10). DP is also often associated with torticollis which usually presents with the child holding their heads to one side due to limited head tilting or rotation (11–13). This leads to the child preference to sleep in one side than the other which in turn leads too DP.

DP results from prolonged external pressure on an infant's skull, particularly at points of surface contact, may inhibit localized cranial growth due to mechanical loading. As a compensatory response, cranial expansion is redirected toward regions experiencing lower compressive forces, frequently resulting in asymmetrical skull development (14–16).

DP is usually diagnosed by physical examination. Imaging modalities such as cranial ultrasound, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan may be used to exclude the presence of craniosynostosis. Various geometric measurements can be used to assess the severity of DP, with the Cranial Vault Asymmetry Index (CVAI) being the most important and commonly relied upon (17, 18).

DP may be treated through counter-positioning therapy, physical therapy, and cranial helmet therapy (CHT). Minor cranial deformity with DP can be treated by counter-positioning therapy, based on the guidelines from the Congress of Neurological Surgeons (CNS), the American Association of Neurological Surgeons (AANS), and the American Academy of Pediatrics (AAP) (19). Moderate DP can be treated using counter-positioning therapy and physical therapy (13, 20). For infants with severe DP, CHT is more effective than relying solely on the natural course of improvement (21, 22).

The effectiveness of CHT in treating DP depends on the infant's age (23). Molding CHT, often made from thermoplastic materials, was recommended to start with infants with severe and mild deformities at the age of 4 and 6 months-old, respectively (24). Plaster of Paris (PoP) is used to capture the skull geometries and produce a positive plaster mold and apply the required rectification; thereafter, thermoplastic material is drapped to have the molding Untreated, DP has been reported to influence cranial shape and potentially impact functional and

developmental outcomes (25, 26). While 85% of the skull growth occurs within the first year of birth (17), this limits the window for early assessment and intervention using CHT (18).

While few studies have explored thermoplastic CHT (21), recent studies (27, 28), have demonstrated the clinical utility of 3D-printed CHT in both Japanese and European cohorts. Therefore, the aim of this study was to assess the effectiveness of 3D-printed CHT in treating infants with DP, in the middle east region.


Methods

Ethical approval was obtained from the Ministry of Health (IRB-409). Medical records from a private medical center were reviewed to identify infants diagnosed with DP and treated using 3D-printed CHT. Rodin4D software (Rodin4D, Eqwal Group, France) was used to extract relevant data, including the infants' age, number of visits, number of helmets used, treatment duration, and CVAI scores.

Data acquisition and measurement procedures

This study involved a retrospective review of clinical records and 3D scan data from a private medical center. A structural sensor scanner with a resolution of $1,280 \times 960$ pixels, synchronized with Rodin4D software (Rodin4D, Eqwal Group, France), was used during treatment to capture the geometry of each infant's head and generate 3D images of the skull (Figure 1). During scanning, the infant's head was positioned neutrally, and anatomical landmarks—including the glabella, opisthocranion, ears, occipital bone, orbital area, exocanthion, and tragion were identified using reference patches placed on the scalp.

The CVAI was measured using diagonal measurements at 30°, following the method of Loveday and de Chalain (29), using Rodin4D software (Rodin4D, Eqwal Group, France). The severity of DP was classified according to the criteria established by Loveday and de Chalain (29). They classified CVAI < 3.5% as



within the normal range (no significant asymmetry), CVAI between 3.5% and 6.25% as mild to moderate plagiocephaly, and $CVAI \ge 6.25\%$ as severe plagiocephaly. Scan durations ranged from 3 to 5 min. The resulting 3D scans were cleaned and processed using Meshmixer software (Autodesk, United States).

3D-helmet design and data processing

As part of the retrospective review, digital records of helmet design workflows were analyzed. Rodin4D-Neo software (Rodin4D, Eqwal Group, France) was used to modify and rectify the scanned 3D skull models captured during clinical treatment. Meshmixer software (Autodesk, United States) was then used to define the helmet trim-line, which was extended from above the glabella to the inferior occipital bone and over vertebra C2. To further customize the design, ZBrush software (Maxon, Germany) was employed to convert the triangular mesh into a quad mesh, allowing for additional editing in CAD software. This process enabled the addition of personal design features such as surface patterns and text (Figure 2).

3D-helmet printing process

As part of the retrospective review, digital records of the 3D helmet printing process were analyzed. The helmet designs originally created using Fusion 360 software (Autodesk, United States). Each helmet weighed approximately 180–220 g. It included 4 mm Plastazote padding for comfort and ventilation holes to improve breathability (Figure 2). Ventilation holes were incorporated to reduce sweating, and Plastazote padding was affixed to the inner surface to absorb pressure and allow for adjustments during follow-up visits.

The finalized 3D designs were sliced using Creality Print software (Creality 3D Technology Co. Ltd., Longhua District, Shenzhen, China), which generated the necessary printer instructions. A cube infill pattern was selected to provide optimal impact resistance, with print parameters adjusted to balance helmet rigidity and flexibility. The following printer settings were recorded: nozzle temperature 220°C, bed temperature 60°C, 60% infill using cube infill type, indirect extrusion, printing speed 180 mm/s, and nozzle size 0.4 mm. Helmets were fabricated using a Creality V3 Plus printer and PET-G (Polyethylene Terephthalate Glycol) filament (Figure 3).

Helmet fitting

Clinical records were reviewed to assess the helmet fitting procedures followed during treatment. After the initial quality check of the 3D-printed helmet, clinicians evaluated helmet readiness and fit. Pressure points were inspected for signs of excessive pressure, friction, or skin irritation. A strap was attached to facilitate easy donning and doffing of the helmet. According to treatment documentation, the helmets were worn for approximately 23 h per day, with regular follow-ups to ensure fit and comfort.

Follow-up and discharge

Follow-up appointments were scheduled every 3–4 weeks. To evaluate the effectiveness of the 3D-printed helmet, the CVAI was recalculated and compared with previous values. If the CVAI remained above 4, a new follow-up appointment was scheduled. Adjustments to the helmet were made using the Plastazote padding to improve fit and comfort. In cases where adjustment was insufficient or the infant's head had outgrown the helmet,




FIGURE 2
3D-design of the helmet: (A) anterior, (B) superior, and (C) lateral views.




FIGURE 3

3D-constructed helmet used in this study: (A) superior, (B) anterior, and (C) lateral views

new measurements were taken to design a replacement helmet. This ensured adaptability and minimized treatment interruptions, potentially leading to improved outcomes.

Statistical analysis

Statistical analysis was conducted using IBM SPSS Statistics version 22. Descriptive statistics (mean \pm SD) summarized infant characteristics and treatment data, including age, number of visits, number of helmets, treatment duration, and CVAI scores. To assess changes in CVAI, a Linear Mixed Model was applied with random intercepts for each participant. Fixed effects included time (pre- vs. post-treatment), gender, age, and treatment duration. The model was estimated using Restricted Maximum Likelihood (REML). A Wilcoxon signed-rank test was also used as a non-parametric confirmation of the CVAI change, given the small sample size. Statistical significance was defined as p < 0.05.

Results

Eleven infants with moderate to severe DP were included in this study. The descriptive characteristics and treatment outcomes for the study participants are summarized in Table 1. Infants initiated 3D-printed helmet therapy at a mean age of 6.4 ± 2.7 months. The average number of clinical visits was 3.8 ± 0.9 , with most infants requiring 1–2 helmets (mean = 1.5 ± 0.5) and undergoing approximately 1.5 ± 0.5 adjustments during treatment. The mean duration of therapy was 9.7 ± 1.7 weeks. No adverse events or complications, such as skin irritation or poor compliance, were reported in the clinical records reviewed.

3D-printed CHT was associated with a statistically and clinically meaningful improvement in cranial symmetry. The CVAI significantly decreased from a pre-treatment mean of $7.7 \pm 2.8\%$ to a post-treatment mean of $3.1 \pm 1.0\%$ (p < 0.001).

TABLE 1 Descriptive statistics of infant characteristics and treatment outcome measures.

Variable	Range	Mean <u>+</u> SD
Age (months)	3–12	6.4 ± 2.7
Number of clinical visits	3–5	3.8 ± 0.9
Number of helmets	1-2	1.5 ± 0.5
Number of adjustments	0-3	1.5 ± 0.5
Treatment duration (weeks)	9–14	9.7 ± 1.7
CVAI before treatment (%)	4-13	7.7 ± 2.8
CVAI after treatment (%)	1-4	3.1 ± 1.0

TABLE 2 Change in CVAI following 3D-printed CHT: linear mixed model results.

Effect	Estimate	Std. error	t-value	p-value
Intercept (baseline CVAI)	0.78	4.56	0.17	0.865
Gender (male vs. female)	-0.03	1.34	-0.02	0.983
Age at treatment initiation (months)	0.15	0.23	0.65	0.514
Treatment duration (weeks)	0.14	0.38	0.36	0.719
CVAI scores (pre-treatment vs. post- treatment)	4.64	0.80	5.79	0.000

Bold indicating statistically significant differences.

A Linear Mixed Model confirmed a significant effect of CVAI score (Estimate = 4.64, SE = 0.80, t = 5.79, p < 0.001), reflecting a consistent and substantial reduction in CVAI after helmet therapy (Table 2).

Other variables included in the model, gender (Estimate = -0.03, p = 0.983), age at the start of treatment (Estimate = 0.15, p = 0.514), and treatment duration (Estimate = 0.14, p = 0.719), were not statistically significant, indicating that the observed improvement was not dependent on these individual factors in this study (Table 2).

To account for the small sample size and validate the primary findings, a Wilcoxon signed-rank test was conducted. The test confirmed a statistically significant reduction in CVAI between baseline and follow-up (Z = -2.84, p = 0.004), supporting the result observed in the Linear Mixed Model.

Discussion

Various treatment options for DP have been reported in the literature, with the most cited being active counter-positioning (ACP) and cranial helmet therapy (CHT). Loveday and de Chalain reported that ACP generally produced slightly better outcomes than CHT, possibly due to challenges associated with helmet manufacturing and fitting (29). However, other studies have found CHT to be more effective than ACP for treating DP (30, 31). CHT is typically indicated for moderate to severe cases (32-34). Additionally, ACP has been shown to require a significantly longer treatment duration—up to two to three times longer than CHT to achieve similar results (29, 33). Side effects associated with CHT are usually mild and can be effectively prevented or managed through proper parental guidance (35, 36). A combination of both ACP and CHT may offer the most effective approach for managing positional plagiocephaly (29). However, in this study only 3D-printed CHT was utilized.

The optimal starting age for CHT in infants with DP remains controversial in the literature. Studies reported that 6 months is the ideal age to initiate CHT (23, 35, 37). This is partly because some researchers argue that CHT is not recommended before 6 months, as rapid brain growth during this period can lead to significant spontaneous improvement (35). However, other studies recommend initiating CHT between 4 and 8 months of age (18, 20, 21, 24, 34, 38). Clarren et al. (35) reported that CHT is effective for treating DP, especially in severe cases when initiated before 6 months of age (37). Several studies have emphasized that an early start, before 4-6 months, is a critical factor in successful treatment, as it takes advantage of the rapid cranial growth during the first year of life (7, 18, 23, 39, 40). Han et al. concluded that initiating CHT after 6 months of age significantly reduced CVAI improvement rates and increased therapy duration (41). In contrast, Aihara et al. found that the starting age has only a small effect on treatment outcomes (2). In the United States, CHT is generally not recommended after the age of 2-years-old, due to the cessation of significant cranial growth (2). In Japan, CHT is generally not recommended after infancy (12 months), as per guidelines from the Japanese Society for Pediatric Neurosurgery, which emphasize limited effectiveness beyond this age (2). In our study, all treated infants were 12 months old or younger, which aligns with previous research. However, no significant correlation was found between age at treatment initiation and treatment outcomes. This may be due to the small sample size and the relatively narrow age range of the treated infants (Table 2).

Many studies have identified male gender as a risk factor for DP (26, 42, 43). Additionally, one study found that affected. But not really ales with a history of uterine constraint were at the highest risk for subsequent school problems (26). In our study, 8 boys and 3 girls were included. However, no significant correlation was found between gender and DP (Table 2), which may be due to the small sample size.

The duration of CHT can impact head circumference and symmetrical ratio. Studies have shown that cranial symmetry improves with longer treatment durations (2). For severe DP, a treatment duration of 8–12 weeks is typically recommended (21,

44, 45). This aligns with the findings of the present study, which reported a duration of 9–14 weeks (Table 1). The number of 3D-printed helmets fitted and the number of adjustments in this study ranged from 1 to 2 and 0–3, respectively, corresponding to the severity of DP in each infant (Table 1). However, no significant differences in cranial vault asymmetry index (CVAI) scores were observed based on treatment duration (Table 2), which may be attributed to the small sample size.

Children with a history of DP may continue to exhibit measurable cranial flattening and asymmetry up to 36 months of age if left untreated (46). Several studies have reported positive outcomes from CHT in treating DP (2, 13, 21, 22, 34, 47, 48). The CVAI was reduced from $7.7 \pm 2.8\%$ to $3.1 \pm 1.0\%$ (Table 1), indicating a shift from severe deformity to a minor level. This evidence demonstrates that 3D-printed CHT is effective in managing DP like the molding CHT. Furthermore, there were statistically significant differences in CVAI scores before and after fitting infants with the 3D-printed helmets (Table 2). This magnitude of change is consistent with prior research demonstrating the effectiveness of helmet therapy. Kluba et al. (23) reported a mean CVAI reduction of 3.5% using traditional molding helmets, while Noto et al. (21) found comparable improvements in a cohort of Japanese infants. Similarly, Kim et al. (49) reported a CVAI reduction of 4.3%, further supporting the therapeutic efficacy of helmet intervention for moderate to severe positional plagiocephaly. Cevik et al. (40) also documented a 3.5% decrease in CVAI, reinforcing the reliability of helmet therapy in achieving clinically significant cranial symmetry. Collectively, these findings validate our results and highlight the consistent impact of helmet therapy across different populations and clinical settings. Although the CVAI scores obtained using the 3D-printed and molded CHT were similar, the 3D-printed approach offers several advantages. It helps keep the infant clean during skull measurements, reduces fear and crying, and saves time and effort for practitioners. Additionally, it provides accurate digital data that can be easily compared during followups. A new helmet can be quickly reprinted in case of loosening or damage, and a variety of designs and colors can be offered. Furthermore, digital measurements can be shared internationally for modification and printing.

In addition to prior studies, Cho et al. (50) investigated the effectiveness of helmet therapy across different cranial shapes and found that the morphological classification of skull deformities may impact treatment response, with asymmetrical types responding more favorably to helmet use. This insight suggests that individualized helmet designs, such as those enabled through 3D printing, could enhance therapeutic outcomes by better accommodating specific cranial geometries.

Similarly, Kim et al. (49) evaluated helmet therapy in infants with moderate to severe positional plagiocephaly and concluded that it led to significant CVAI improvements, reinforcing the role of helmeting as a primary intervention. Their findings align with our results, particularly in demonstrating that CVAI reductions are substantial and clinically meaningful even with a modest treatment duration, further validating the applicability of 3D-printed helmets.

Van Cruchten and Feijen (51) conducted a 5-year follow-up study, emphasizing the sustained benefits of helmet therapy over time. Their long-term perspective underscores the importance of early and effective treatment to ensure lasting correction of cranial asymmetry. These results support our current outcomes and highlight the potential for 3D-printed helmet therapy to achieve similarly enduring results, especially given its precision and adaptability.

Finally, it is worth emphasizing that 3D printing offers a substantial cost advantage. The average cost of a 3D-printed helmet in our study was approximately \$150 USD, in contrast to traditional molded helmets, which often range between \$300 and 500 USD. In resource-limited settings or national health systems where cost-effectiveness is crucial, this reduction in material and labor costs could facilitate broader access to cranial orthoses. Moreover, 3D printing allows for rapid prototyping, quick reprints in case of fit issues, and personalized cosmetic features—all without compromising clinical effectiveness.

Conclusion

This study demonstrated that CHT, including those produced using 3D printing, effectively reduced cranial asymmetry in infants with mild to severe DP. Initiating treatment before 6 months of age was associated with more favourable outcomes. The reduction in asymmetry, as measured by the CVAI, was statistically significant and consistent across age, gender, and duration of helmet use, underscoring the broad clinical applicability of CHT. While these findings support the use of CHT in managing DP, the specific contribution of the 3D-printing method to treatment outcomes remains unclear. Further research involving larger, more diverse cohorts is warranted to confirm these results and explore whether manufacturing methods influence clinical effectiveness or offer other practical advantages, such as customization or cost-efficiency.

Study limitations

This study is limited by its small sample size (n=11) and retrospective design, which restricts the generalizability of the findings and precludes a detailed cost-effectiveness analysis. The sample size was constrained by the fact that only one center in Jordan currently provides 3D-printed cranial helmet therapy (CHT), limiting the ability to assess the effects of multiple variables. Additionally, a longitudinal follow-up may be valuable to evaluate the long-term effects of deformational plagiocephaly (DP) on head shape as children grow.

Nevertheless, the use of 3d printing presents a promising avenue for scalable and individualized cranial orthoses, a detailed cost analysis per patient was not feasible due to the small cohort size. Future research should include cost-effectiveness assessments, especially when considering broader implementation in low-resource settings.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the Ministry of Health—Jordan (IRB-409). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

HA: Conceptualization, Supervision, Investigation, Writing – review & editing, Writing – original draft, Project administration. RN: Software, Formal analysis, Writing – original draft, Data curation. RA: Software, Formal analysis, Writing – original draft, Data curation. TQ: Writing – original draft, Formal analysis, Software, Data curation. MA: Visualization, Methodology, Validation, Writing – review & editing. AA: Writing – review & editing, Methodology, Visualization, Validation. AS: Investigation, Writing – original draft, Conceptualization. AM: Supervision, Writing – review & editing, Validation, Formal analysis, Visualization. ED: Validation, Software, Writing – original draft. DV: Writing – original draft, Software, Validation. BM: Writing – review & editing, Validation, Resources, Supervision.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- 1. Panchal J, Amirsheybani H, Gurwitch R, Cook V, Francel P, Neas B, et al. Neurodevelopment in children with single-suture craniosynostosis and plagiocephaly without synostosis. *Plast Reconstr Surg.* (2001) 108(6):1492–8. doi: 10. 1097/00006534-200111000-00007
- 2. Aihara Y, Chiba K, Kawamata T. Helmet therapy efficacy and its prediction in Japanese infants with positional plagio-and brachycephaly. *Childs Nerv Syst.* (2024) 40(7):2135–44. doi: 10.1007/s00381-024-06370-3
- 3. Jung BK, Yun IS. Diagnosis and treatment of positional plagiocephaly. Arch Craniofac Surg. (2020) 21(2):80–6. doi: 10.7181/acfs.2020.00059
- 4. Hutchison BL, Hutchison LA, Thompson JM, Mitchell EA. Plagiocephaly and brachycephaly in the first two years of life: a prospective cohort study. *Pediatrics*. (2004) 114(4):970–80. doi: 10.1542/peds.2003-0668-F
- 5. Purnell CA, Benz AW, Gosain AK. Assessment of head shape by craniofacial teams: structuring practice parameters to optimize efficiency. *J Craniofac Surg.* (2015) 26(6):1808–11. doi: 10.1097/SCS.000000000001948
- 6. Kattwinkel J, Brooks J, Myerberg D. Positioning and SIDS. *Pediatrics*. (1992) 89(6):1120–6. doi: 10.1542/peds.89.6.1120
- 7. Kawaguchi Y, Matsushita A, Kawai T, Furuta S. Handlings of infants with oblique posture. *Orthop Traumatol.* (1980) 29(2):197–201. doi: 10.5035/nishiseisai.29.197
- 8. van Vlimmeren LA, van der Graaf Y, Boere-Boonekamp MM, L'Hoir MP, Helders PJ, Engelbert RH. Risk factors for deformational plagiocephaly at birth and at 7 weeks of age: a prospective cohort study. *Pediatrics*. (2007) 119(2):e408–18. doi: 10.1542/peds.2006-2012
- 9. Argenta LC, David LR, Wilson JA, Bell WO. An increase in infant cranial deformity with supine sleeping position. *J Craniofac Surg.* (1996) 7(1):5–11. doi: 10.1097/00001665-199601000-00005
- 10. Najarian SP. Infant cranial molding deformation and sleep position: implications for primary care. *J Pediatr Health Care*. (1999) 13(4):173–7. doi: 10.1016/S0891-5245 (99)90036-6
- 11. O'Broin E, Allcutt D, Earley MJ. Posterior plagiocephaly: proactive conservative management. *Br J Plast Surg.* (1999) 52(1):18–23. doi: 10.1054/bjps.1997.3007
- 12. Fernbach SK, McAlister WH. Craniosynostosis 1998: concepts and controversies: invited commentary: posterior deformational plagiocephaly. *Pediatr Radiol.* (1998) 28(9):722–8. doi: 10.1007/s002470050452
- 13. Moss SD. Nonsurgical, nonorthotic treatment of occipital plagiocephaly: what is the natural history of the misshapen neonatal head? *J Neurosurg.* (1997) 87(5):667–70. doi: 10.3171/jns.1997.87.5.0667
- 14. Inchingolo AD, Inchingolo AM, Piras F, Malcangi G, Patano A, Di Pede C, et al. A systematic review of positional plagiocephaly prevention methods for patients in development. *Appl Sci.* (2022) 12(21):11172. doi: 10.3390/app122111172
- 15. Beuriat P-A, Szathmari A, Di Rocco F, Mottolese CA. Deformational plagiocephaly: state of the art and review of the literature. *Neurochirurgie.* (2019) 65(5):322–9. doi: 10.1016/j.neuchi.2019.09.003
- 16. Kunz F, Schweitzer T, Große S, Waßmuth N, Stellzig-Eisenhauer A, Böhm H, et al. Head orthosis therapy in positional plagiocephaly: longitudinal 3D-investigation of long-term outcomes, compared with untreated infants and with a control group. *Eur J Orthod.* (2019) 41(1):29–37. doi: 10.1093/ejo/cjy012
- 17. Biggs WS. Diagnosis and management of positional head deformity. Am Fam Physician. (2003) 67(9):1953–6.
- 18. Mortenson P, Steinbok P, Smith D. Deformational plagiocephaly and orthotic treatment: indications and limitations. *Childs Nerv Syst.* (2012) 28:1407–12. doi: 10.1007/s00381-012-1755-3
- 19. Tamber MS, Nikas D, Beier A, Baird LC, Bauer DF, Durham S, et al. Congress of neurological surgeons systematic review and evidence-based guideline on the role of cranial molding orthosis (helmet) therapy for patients with positional plagiocephaly. *Neurosurgery.* (2016) 79(5):E632–3. doi: 10.1227/NEU.000000000001430
- 20. Fahrenkopf M, Adams N, Mann R, Girotto J. Deformational plagiocephaly. In: Kliegman R, St Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, editors. *Nelson Textbook of Pediatrics*. 21 ed. Philadelphia, PA: Elsevier (2020). p. 3082–6.
- 21. Noto T, Nagano N, Kato R, Hashimoto S, Saito K, Miyabayashi H, et al. Natural-course evaluation of infants with positional severe plagiocephaly using a

- three-dimensional scanner in Japan: comparison with those who received cranial helmet therapy. *J Clin Med.* (2021) 10(16):3531. doi: 10.3390/jcm10163531
- 22. Kim SY, Park M-S, Yang J-I, Yim S-Y. Comparison of helmet therapy and counter positioning for deformational plagiocephaly. *Ann Rehabil Med.* (2013) 37(6):785–95. doi: 10.5535/arm.2013.37.6.785
- 23. Kluba S, Kraut W, Reinert S, Krimmel MJP, Surgery R. What is the optimal time to start helmet therapy in positional plagiocephaly? *Plast Reconstr Surg.* (2011) 128(2):492–8. doi: 10.1097/PRS.0b013e31821b62d6
- 24. Aihara Y, Komatsu K, Dairoku H, Kubo O, Hori T, Okada Y. Cranial molding helmet therapy and establishment of practical criteria for management in Asian infant positional head deformity. *Childs Nerv Syst.* (2014) 30:1499–509. doi: 10.1007/s00381-014-2471-y
- 25. Martiniuk AL, Vujovich-Dunn C, Park M, Yu W, Lucas B, Pediatrics B. Plagiocephaly and developmental delay: a systematic review. *J Dev Behav Pediatr*. (2017) 38(1):67–78. doi: 10.1097/DBP.00000000000376
- 26. Miller RI, Clarren SK. Long-term developmental outcomes in patients with deformational plagiocephaly. *Pediatrics*. (2000) 105(2):e26. doi: 10.1542/peds.105.2.
- 27. Kajita H, Tanaka I, Komuro H, Nishimaki S, Kusakawa I, Sakamoto K. Efficacy of cranial orthosis for plagiocephaly based on 2D and 3D evaluation. *Arch Plast Surg.* (2024) 51(02):169–81. doi: 10.1055/a-2222-1494
- 28. Nagano N, Kato R, Noto T, Hijikata M, Okahashi A, Nakanomori A, et al. Therapeutic effectiveness of a novel cranial remolding helmet (baby band2) for positional plagiocephaly: a multicenter clinical observational study. *J Clin Med.* (2024) 13(19):5952. doi: 10.3390/jcm13195952
- 29. Loveday BP, de Chalain T. Active counterpositioning or orthotic device to treat positional plagiocephaly? *J Craniofac Surg.* (2001) 12(4):308–13. doi: 10.1097/00001665-200107000-00003
- 30. Lipira AB, Gordon S, Darvann TA, Hermann NV, Van Pelt AE, Naidoo SD, et al. Helmet versus active repositioning for plagiocephaly: a three-dimensional analysis. *Pediatrics.* (2010) 126(4):e936–45. doi: 10.1542/peds.2009-1249
- 31. Xia JJ, Kennedy KA, Teichgraeber JF, Wu KQ, Baumgartner JB, Gateno J, et al. Nonsurgical treatment of deformational plagiocephaly: a systematic review. *Arch Pediatr Adolesc Med.* (2008) 162(8):719–27. doi: 10.1001/archpedi.162.8.719
- 32. Teichgraeber JF, Seymour-Dempsey K, Baumgartner JE, Xia JJ, Waller AL, Gateno J. Molding helmet therapy in the treatment of brachycephaly and plagiocephaly. *J Craniofac Surg.* (2004) 15(1):118–23. doi: 10.1097/00001665-200401000-00031
- 33. Vles J, Colla C, Weber J, Beuls E, Wilmink J, Kingma H. Helmet versus nonhelmet treatment in nonsynostotic positional posterior plagiocephaly. *J Craniofac Surg.* (2000) 11(6):572–4. doi: 10.1097/00001665-200011060-00010
- 34. Kluba S, Kraut W, Calgeer B, Reinert S, Krimmel M. Treatment of positional plagiocephaly–helmet or no helmet? *J Cranio-Maxillofacial Surg.* (2014) 42(5):683–8. doi: 10.1016/j.jcms.2013.09.015
- 35. Clarren SK. Plagiocephaly and torticollis: etiology, natural history, and helmet treatment. *J Pediatr*. (1981) 98(1):92–5. doi: 10.1016/S0022-3476(81)80549-5
- 36. Wilbrand J-F, Wilbrand M, Malik CY, Howaldt H-P, Streckbein P, Schaaf H, et al. Complications in helmet therapy. *J Craniomaxillofac Surg.* (2012) 40(4):341–6. doi: 10.1016/j.jcms.2011.05.007
- 37. Freudlsperger C, Steinmacher S, Saure D, Bodem JP, Kühle R, Hoffmann J, et al. Impact of severity and therapy onset on helmet therapy in positional plagiocephaly. *J Craniomaxillofac Surg.* (2016) 44(2):110–5. doi: 10.1016/j.jcms.2015.11.016
- 38. Yoo H-S, Rah DK, Kim YO. Outcome analysis of cranial molding therapy in nonsynostotic plagiocephaly. *Arch Plast Surg.* (2012) 39(04):338–44. doi: 10.5999/aps.2012.39.4.338
- 39. Lam S, Pan I-W, Strickland BA, Hadley C, Daniels B, Brookshier J, et al. Factors influencing outcomes of the treatment of positional plagiocephaly in infants: a 7-year experience. *J Neurosurg Pediatr.* (2017) 19(3):273–81. doi: 10.3171/2016.9.PEDS16275
- 40. Çevik S, Işık S, Özkılıç A. The role of age on helmet therapy in deformational plagiocephaly and asymmetric brachycephaly. *Childs Nerv Syst.* (2020) 36:803–10. doi: 10.1007/s00381-019-04354-2

- 41. Han M-H, Kang JY, Han HY, Cho Y-H, Jang D-H. Relationship between starting age of cranial-remolding-orthosis therapy and effectiveness of treatment in children with deformational plagiocephaly. *Childs Nerv Syst.* (2017) 33:1349–56. doi: 10. 1007/s00381-017-3427-9
- 42. McKinney CM, Cunningham ML, Holt VL, Leroux B, Starr JR. A case-control study of infant, maternal and perinatal characteristics associated with deformational plagiocephaly. *Paediatr Perinat Epidemiol.* (2009) 23(4):332–45. doi: 10.1111/j.1365-3016.2009.01038.x
- 43. David DJ, Menard R. Occipital plagiocephaly. Br J Plast Surg. (2000) 53(5):367-77. doi: 10.1054/bjps.2000.3329
- 44. Robinson S, Proctor M. Diagnosis and management of deformational plagiocephaly: a review. *J Neurosurg Pediatr.* (2009) 3(4):284–95. doi: 10.3171/2009. 1.PEDS08330
- 45. Flannery ABK, Looman WS, Kemper K. Evidence-based care of the child with deformational plagiocephaly, part II: management. *J Pediatr Health Care.* (2012) 26(5):320–31. doi: 10.1016/j.pedhc.2011.10.002
- 46. Collett BR, Leroux BG, Wallace ER, Gallagher E, Shao J, Speltz ML. Head shape at age 36 months among children with and without a history of positional skull deformation. *J Neurosurg Pediatr.* (2018) 21(3):204–13. doi: 10.3171/2017.7.PEDS16693

- 47. Kelly KM, Littlefield TR, Pomatto JK, Manwaring KH, Beals SP. Cranial growth unrestricted during treatment of deformational plagiocephaly. *Pediatr Neurosurg.* (1999) 30(4):193–9. doi: 10.1159/000028794
- 48. Schweitzer T, Böhm H, Linz C, Jager B, Gerstl L, Kunz F, et al. Three-dimensional analysis of positional plagiocephaly before and after molding helmet therapy in comparison to normal head growth. *Childs Nerv Syst.* (2013) 29:1155–61. doi: 10.1007/s00381-013-2030-y
- 49. Kim J, Kim J, Chae KY. Effectiveness of helmet therapy for infants with moderate to severe positional plagiocephaly. *Clin Exp Pediatr.* (2023) 67(1):46–53. doi: 10.3345/cep.2023.00626
- 50. Cho HG, Ryu JY, Lee JS, Yang JD, Chung HY, Choi KY. A study on the effectiveness of helmet therapy for cranial deformations according to cranial shape. J Craniofac Surg. (2024) 35(3):779–82. doi: 10.1097/SCS.0000000000010018
- 51. van Cruchten C, Feijen MMW. Helmet therapy for positional cranial deformations; a 5-year follow-up study. J Craniomaxillofac Surg. (2022) 50(6):499–503. doi: $10.1016/\mathrm{j.j.cms.}.2022.05.001$